Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

ceftolozane-tazobactam

  • Open Access
    Molecular Characterization of Baseline <em>Enterobacterales</em> and <span class="named-content genus-species" id="named-content-1">Pseudomonas aeruginosa</span> Isolates from a Phase 3 Nosocomial Pneumonia (ASPECT-NP) Clinical Trial
    Mechanisms of Resistance
    Molecular Characterization of Baseline Enterobacterales and Pseudomonas aeruginosa Isolates from a Phase 3 Nosocomial Pneumonia (ASPECT-NP) Clinical Trial

    We evaluated β-lactam-resistant baseline Enterobacterales species and Pseudomonas aeruginosa lower respiratory tract isolates collected during the ASPECT-NP phase 3 clinical trial evaluating the safety and efficacy of ceftolozane-tazobactam compared with meropenem for the treatment of nosocomial pneumonia in ventilated adults. Isolates were subjected to whole...

    Mariana Castanheira, Matthew G. Johnson, Brian Yu, Jennifer A. Huntington, Patricia Carmelitano, Christopher Bruno, Elizabeth G. Rhee, Mary Motyl
  • Open Access
    Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain
    Clinical Therapeutics
    Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain

    The aim of this study was to describe the pharmacokinetics of ceftolozane-tazobactam in plasma and cerebrospinal fluid (CSF) of infected critically ill patients. In a prospective observational study, critically ill patients (≥18 years) with an indwelling external ventricular drain received a single intravenous dose of 3.0 g ceftolozane-tazobactam. Serial plasma and CSF samples were collected for measurement of unbound ceftolozane and...

    Fekade B. Sime, Melissa Lassig-Smith, Therese Starr, Janine Stuart, Saurabh Pandey, Suzanne L. Parker, Steven C. Wallis, Jeffrey Lipman, Jason A. Roberts
  • Antimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of <span class="named-content genus-species" id="named-content-1">Haemophilus influenzae</span> from the United States and Europe
    Susceptibility
    Antimicrobial Activity of Ceftolozane-Tazobactam and Comparators against Clinical Isolates of Haemophilus influenzae from the United States and Europe

    Nine hundred Haemophilus influenzae clinical isolates from 83 U.S. and European medical centers were tested for susceptibility by reference broth microdilution methods against ceftolozane-tazobactam and comparators. Results were stratified by β-lactamase production and infection type. Overall, ceftolozane-tazobactam MIC50/90 values were 0.12/0.25 mg/liter,...

    Helio S. Sader, Cecilia G. Carvalhaes, Leonard R. Duncan, Dee Shortridge
  • Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant <span class="named-content genus-species" id="named-content-1">Pseudomonas aeruginosa</span>, Including High-Risk Clones, in an <em>In Vitro</em> Pharmacodynamic Model
    Experimental Therapeutics
    Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an In Vitro Pharmacodynamic Model

    Combination therapy is an attractive therapeutic option for extensively drug-resistant (XDR) Pseudomonas aeruginosa infections. Colistin has been the only treatment available for these infections for many years, but its results are suboptimal. Ceftolozane-tazobactam (C/T) is a newly available therapeutic option that has shown good antipseudomonal activity, even...

    María Montero, Sandra Domene Ochoa, Carla López-Causapé, Brian VanScoy, Sonia Luque, Luisa Sorlí, Núria Campillo, Ariadna Angulo-Brunet, Eduardo Padilla, Núria Prim, Virginia Pomar, Alba Rivera, Santiago Grau, Paul G. Ambrose, Antonio Oliver, Juan P. Horcajada
  • Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections
    Clinical Therapeutics
    Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections

    Our objective was to describe the prescribing practices, clinical characteristics, and outcomes of patients treated with ceftolozane-tazobactam (C/T) for multidrug-resistant (MDR) Gram-negative infections. This was a multicenter, retrospective, cohort study at eight U.S. medical centers (2015 to 2019). Inclusion criteria were age ≥18 years and receipt of C/T (≥72 hours) for suspected or confirmed MDR Gram-negative infection. The primary...

    Sarah C. J. Jorgensen, Trang D. Trinh, Evan J. Zasowski, Abdalhamid M. Lagnf, Samuel P. Simon, Sahil Bhatia, Sarah M. Melvin, Molly E. Steed, Natalie A. Finch, Taylor Morrisette, Sandy J. Estrada, Joshua R. Rosenberg, Susan L. Davis, Michael J. Rybak
  • Open Access
    A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration
    Pharmacology
    A Population Pharmacokinetic Model-Guided Evaluation of Ceftolozane-Tazobactam Dosing in Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration

    The aim of this work was to describe optimized dosing regimens of ceftolozane-tazobactam for critically ill patients receiving continuous venovenous hemodiafiltration (CVVHDF). We conducted a prospective observational pharmacokinetic study in adult critically ill patients with clinical indications for ceftolozane-tazobactam and CVVHDF. Unbound drug concentrations were measured from serial prefilter blood, postfilter blood, and...

    Fekade B. Sime, Melissa Lassig-Smith, Therese Starr, Janine Stuart, Saurabh Pandey, Suzanne L. Parker, Steven C. Wallis, Jeffrey Lipman, Jason A. Roberts
  • <em>In Vitro</em> Activities of β-Lactam–β-Lactamase Inhibitor Antimicrobial Agents against Cystic Fibrosis Respiratory Pathogens
    Clinical Therapeutics
    In Vitro Activities of β-Lactam–β-Lactamase Inhibitor Antimicrobial Agents against Cystic Fibrosis Respiratory Pathogens

    We tested the in vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, piperacillin-tazobactam, and 11 other antimicrobial agents against 420 Burkholderia, Achromobacter, Stenotrophomonas, and Pandoraea strains, 89% of which were cultured from respiratory specimens from persons with cystic fibrosis.

    Lindsay J. Caverly, Theodore Spilker, Linda M. Kalikin, Terri Stillwell, Carol Young, David B. Huang, John J. LiPuma
  • Ceftolozane Pharmacokinetics in a Septic Critically Ill Patient under Different Extracorporeal Replacement Therapies
    Letter to the Editor
    Ceftolozane Pharmacokinetics in a Septic Critically Ill Patient under Different Extracorporeal Replacement Therapies
    Nieves Carbonell, Gerardo Aguilar, Rafael Ferriols, Rotzel Huerta, José Ferreres, Marisa Calabuig, Mar Juan, Carlos Ezquer, Javier Colomina, M. Luisa Blasco
  • Emergence of Resistance to Novel β-Lactam–β-Lactamase Inhibitor Combinations Due to Horizontally Acquired AmpC (FOX-4) in <em>Pseudomonas aeruginosa</em> Sequence Type 308
    Letter to the Editor
    Emergence of Resistance to Novel β-Lactam–β-Lactamase Inhibitor Combinations Due to Horizontally Acquired AmpC (FOX-4) in Pseudomonas aeruginosa Sequence Type 308
    Pablo A. Fraile-Ribot, Cristóbal del Rosario-Quintana, Carla López-Causapé, María A. Gomis-Font, Mar Ojeda-Vargas, Antonio Oliver
  • A 2.5-Year Within-Patient Evolution of <span class="named-content genus-species" id="named-content-1">Pseudomonas aeruginosa</span> Isolates with <em>In Vivo</em> Acquisition of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Resistance upon Treatment
    Editor's Pick Mechanisms of Resistance
    A 2.5-Year Within-Patient Evolution of Pseudomonas aeruginosa Isolates with In Vivo Acquisition of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Resistance upon Treatment

    Ceftolozane-tazobactam is considered to be a last-resort treatment for infections caused by multidrug-resistant (MDR) Pseudomonas aeruginosa. Although resistance to this antimicrobial has been described in vitro, the development of resistance in vivo has rarely been reported. Here, we describe the evolution of resistance to ceftolozane-tazobactam of...

    Thibaud Boulant, Agnès B. Jousset, Rémy A. Bonnin, Aurélie Barrail-Tran, Adrien Borgel, Saoussen Oueslati, Thierry Naas, Laurent Dortet

Pages

  • Next
  • 1
  • 2
  • 3
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596